Cervomed vs Cytomed Therapeutics
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $248,384 for Cytomed Therapeutics (16.1 times as much). Cytomed Therapeutics grew faster (377.5% against -58.9%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -1227.1%. Cervomed carries less debt relative to equity (0.0% against 6.3%).
| Latest fiscal year | CervomedCRVO, 2025 | Cytomed TherapeuticsGDTC, 2025 |
|---|---|---|
| Revenue | $4.0m | $248,384 |
| Revenue growth | -58.9% | 377.5% |
| Net income | −$27.0m | −$3.0m |
| Operating margin | -706.2% | — |
| Net margin | -673.1% | -1227.1% |
| Return on equity | -93.9% | -52.3% |
| Free cash flow | −$23.4m | −$3.3m |
| Cash | $8.2m | $1.6m |
| Total debt | $0 | $318,456 |
| Debt to equity | 0.0% | 6.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 15 | — |
| Market value | $21.0m | $10.2m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 19 buys, 0 sales | 5 buys, 0 sales |